Q1 Earnings Estimate for AUTL Issued By HC Wainwright

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – HC Wainwright issued their Q1 2026 earnings estimates for shares of Autolus Therapeutics in a report released on Tuesday, February 17th. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.28) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.11) EPS and FY2029 earnings at ($0.42) EPS.

Other research analysts also recently issued research reports about the company. Zacks Research lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 21st. Needham & Company LLC dropped their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, January 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Five analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $8.50.

Autolus Therapeutics Stock Up 1.8%

Autolus Therapeutics stock opened at $1.67 on Thursday. The firm has a fifty day simple moving average of $1.58 and a two-hundred day simple moving average of $1.57. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $2.70. The company has a market capitalization of $444.45 million, a PE ratio of -2.01 and a beta of 1.98.

Institutional Trading of Autolus Therapeutics

Several large investors have recently bought and sold shares of the company. Armistice Capital LLC grew its position in shares of Autolus Therapeutics by 9.1% in the 2nd quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock worth $27,360,000 after buying an additional 1,000,000 shares during the period. TFG Asset Management GP Ltd increased its stake in shares of Autolus Therapeutics by 10.5% in the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock worth $21,660,000 after acquiring an additional 900,000 shares in the last quarter. Cetera Investment Advisers lifted its position in Autolus Therapeutics by 17.6% during the 2nd quarter. Cetera Investment Advisers now owns 617,172 shares of the company’s stock valued at $1,407,000 after acquiring an additional 92,300 shares during the period. R Squared Ltd bought a new stake in Autolus Therapeutics during the second quarter worth about $50,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Autolus Therapeutics during the second quarter worth about $1,288,000. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.